Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis

Takeshi Nakahara, Hiroshi Morimoto, Naofumi Murakami, Masutaka Furue

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

More than 15 years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids. Tacrolimus is a potent immunosuppressant. However, recent studies have revealed its diverse action on the cardinal pathomechanisms of atopic dermatitis. In this review, we summarize the mechanistic role of tacrolimus in various aspects of allergic inflammation including mast cell activation, innate allergic response, pruritus, sensory nerve activation, and skin barrier dysfunction.

Original languageEnglish
Pages (from-to)233-238
Number of pages6
JournalPediatric Allergy and Immunology
Volume29
Issue number3
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Tacrolimus
Atopic Dermatitis
Steroids
Skin
Pruritus
Immunosuppressive Agents
Mast Cells
Atrophy
Clinical Trials
Guidelines
Inflammation
Safety

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

Cite this

Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis. / Nakahara, Takeshi; Morimoto, Hiroshi; Murakami, Naofumi; Furue, Masutaka.

In: Pediatric Allergy and Immunology, Vol. 29, No. 3, 01.05.2018, p. 233-238.

Research output: Contribution to journalReview article

@article{240931ae075f4b659551f9dbb409c603,
title = "Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis",
abstract = "More than 15 years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids. Tacrolimus is a potent immunosuppressant. However, recent studies have revealed its diverse action on the cardinal pathomechanisms of atopic dermatitis. In this review, we summarize the mechanistic role of tacrolimus in various aspects of allergic inflammation including mast cell activation, innate allergic response, pruritus, sensory nerve activation, and skin barrier dysfunction.",
author = "Takeshi Nakahara and Hiroshi Morimoto and Naofumi Murakami and Masutaka Furue",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/pai.12842",
language = "English",
volume = "29",
pages = "233--238",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "3",

}

TY - JOUR

T1 - Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis

AU - Nakahara, Takeshi

AU - Morimoto, Hiroshi

AU - Murakami, Naofumi

AU - Furue, Masutaka

PY - 2018/5/1

Y1 - 2018/5/1

N2 - More than 15 years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids. Tacrolimus is a potent immunosuppressant. However, recent studies have revealed its diverse action on the cardinal pathomechanisms of atopic dermatitis. In this review, we summarize the mechanistic role of tacrolimus in various aspects of allergic inflammation including mast cell activation, innate allergic response, pruritus, sensory nerve activation, and skin barrier dysfunction.

AB - More than 15 years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids. Tacrolimus is a potent immunosuppressant. However, recent studies have revealed its diverse action on the cardinal pathomechanisms of atopic dermatitis. In this review, we summarize the mechanistic role of tacrolimus in various aspects of allergic inflammation including mast cell activation, innate allergic response, pruritus, sensory nerve activation, and skin barrier dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=85045905145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045905145&partnerID=8YFLogxK

U2 - 10.1111/pai.12842

DO - 10.1111/pai.12842

M3 - Review article

C2 - 29205511

AN - SCOPUS:85045905145

VL - 29

SP - 233

EP - 238

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 3

ER -